8-K: Johnson & Johnson Reports Strong Q1 2025 Results and Announces Dividend Increase

Johnson & Johnson announces a 2.4% increase in first-quarter sales to $21.9 billion and a 4.8% increase in the quarterly dividend, marking the 63rd consecutive year of dividend growth.

Summary

• Johnson & Johnson reported a 2.4% increase in first-quarter sales, reaching $21.9 billion.
• Operational sales grew by 4.2%, while adjusted operational sales increased by 3.3%.
• Earnings per share (EPS) increased to $4.54, including the reversal of special charges.
• Adjusted EPS increased to $2.77, a 2.2% increase.
• The company is increasing its full-year 2025 operational sales guidance to reflect the acquisition of CAPLYTA.
• The company maintains its full-year 2025 adjusted reported EPS outlook of 6.2% growth at the mid-point.
• The Board of Directors declared a 4.8% increase in the quarterly dividend, from $1.24 to $1.30 per share.
• The annual dividend rate is now $5.20 per share, up from $4.96 per share.
• The next quarterly dividend is payable on June 10, 2025, to shareholders of record on May 27, 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong financial results, a dividend increase, and promising pipeline developments. The company's diversified portfolio and strategic acquisitions contribute to a favorable sentiment.

Positives

• Strong first-quarter sales growth, with a 2.4% increase to $21.9 billion.
• Operational sales growth of 4.2% indicates healthy underlying business performance.
• Increase in EPS and adjusted EPS demonstrates improved profitability.
• Dividend increase of 4.8% reflects confidence in the company's financial stability and commitment to shareholders.
• Positive momentum in Innovative Medicine and MedTech segments, driven by key products and acquisitions.
• The company is increasing its full-year 2025 operational sales guidance.
• Significant new product pipeline progress including approval of TREMFYA in Crohns disease, data for RYBREVANT/LAZCLUZE overall survival in non-small cell lung cancer and icotrokinra in plaque psoriasis, and initiation of the clinical trial for a general surgery robotic system, OTTAVA.

Negatives

• Currency translation had a negative impact on sales, reducing reported sales growth.
• STELARA sales were down significantly, impacting overall Immunology sales.
• Some products, like IMBRUVICA and INVEGA SUSTENNA, experienced sales declines.
• Research and development expense decreased by 8.9%.

Risks

• The company faces risks related to economic factors, competition, and regulatory approvals.
• Product efficacy or safety concerns could lead to recalls or regulatory action.
• Significant adverse litigation, including product liability claims, could impact financial results.
• Changes in healthcare laws and regulations could affect the company's business.
• The company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort.

Future Outlook

The company is increasing its full-year 2025 operational sales guidance and maintains its full-year 2025 adjusted reported EPS outlook of 6.2% growth at the mid-point.

Management Comments

• Joaquin Duato, Chairman and Chief Executive Officer, stated, 'The power of Johnson & Johnsons uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance.'
• Joaquin Duato also mentioned the company fortified its position as an innovation powerhouse with major advancements across its pipeline.

Industry Context

Johnson & Johnson's diversified portfolio allows it to perform steadily across different healthcare sectors. The acquisition of Intra-Cellular Therapies strengthens its position in neuroscience. The company's focus on innovation, including new drug approvals and robotic surgery systems, positions it to compete effectively in the evolving healthcare landscape.

Comparison to Industry Standards

• Johnson & Johnson's growth in Innovative Medicine is comparable to other major pharmaceutical companies like Pfizer and Novartis, which are also focusing on oncology and immunology.
• In the MedTech sector, J&J's growth is in line with companies like Medtronic and Stryker, which are also seeing growth in cardiovascular and surgical products.
• The dividend increase reflects a commitment to shareholder value, similar to other established healthcare companies like Abbott and AbbVie.
• The company's focus on robotic surgery with the OTTAVA system puts it in competition with Intuitive Surgical, the leader in the robotic surgery market.

Stakeholder Impact

• Shareholders will benefit from the increased dividend.
• Employees may see opportunities for growth and development within the company.
• Customers will have access to new and innovative healthcare solutions.
• The company's performance supports its relationships with suppliers and creditors.

Next Steps

• The company will continue to focus on innovation and product development.
• Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time.

Key Dates

Keywords

Johnson & Johnson, Financial Results, Dividend, Sales Growth, Earnings, Pharmaceuticals, Medical Devices, JNJ, Q1 2025